Merck reports two Phase 3 study misses for Keytruda

Merck & Co.’s cancer immunotherapy Keytruda has come up short in two Phase 3 trials, one in prostate cancer and another in advanced lung cancer, the company said Tuesday, limiting two avenues for further widening of the drug’s use.